Month: August 2021

Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2, placebo-controlled RESCUE-ALS trial remains on track for top-line data in 2H 2021 Interim blinded RESCUE-ALS efficacy data suggest CNM-Au8®, a gold nanocrystal suspension, may have neuro-reparative potential in people with amyotrophic lateral sclerosis Cash of $63 million as of June 30, 2021 SALT LAKE CITY, Aug. 10, 2021 (GLOBE NEWSWIRE) — Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today reported its second quarter 2021 operating and financial results. “Our...

Former Sam Adams CMO Robert Hall to Serve as Senior Brand and Marketing Advisor Kevin Compagna Joins MariMed as VP, Wholesale & Licensing for North America NORWOOD, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — MariMed Inc. (MRMD:OTCQX) (the “Company” or “MariMed”), a leading multi-state cannabis operator focused on health and wellness, today announced a series of appointments intended to help the company drive sales of its award-winning brand portfolio.Senior CPG marketer and former Sam Adams beer Chief Marketing Officer, Robert Hall, has been appointed as a Senior Brand and Marketing Advisor to MariMed. In that capacity, he will help MariMed establish data-supported, distinct brand strategies and brand building techniques as the Company expands the distribution of its top selling brands and products across...

Nears Completion of Transformational Green Shift to Tactical Decarbonization VIRGINIA CITY, Nev., Aug. 10, 2021 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”), an emerging innovator and leader in the sustainable extraction, valorization, and production of high value strategic materials that are essential to meeting the rapidly increasing global demand for clean energy, carbon-neutrality, and natural products, today announced its unaudited financial results for the periods ended June 30, 2021: Selected Strategic HighlightsNet income of $1.9 million for the six months ended June 30, 2021, or $0.05 per basic and diluted share, inclusive of $2.6 million in net gains related to the change in fair value of certain assets. Net increase in shareholders’ equity of $38.5 million for the six months ended...

– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from second cohort anticipated September 2021 – – Positive recent FDA feedback on MAT2501 (oral amikacin) development program allows for initiation of Phase 1 study in healthy volunteers in Q4 2021 – – In vitro studies of lipid nanocrystal (LNC) formulations of Gilead Sciences’ remdesivir demonstrate meaningful efficacy compared to free remdesivir, with a favorable toxicity profile; National Institute of Allergy and Infectious Diseases (NIAID) preparing to initiate an in vivo efficacy study of LNC-remdesivir in Q3 2021 – – Management to host conference call today, Tuesday, August 10th, at 8:00 a.m. ET – BEDMINSTER, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE)...

  10 August 2021   Mothercare plc (“the Company”)  NOTICE OF AGM AND POSTING OF ANNUAL REPORT   Mothercare plc, the leading specialist global brand for parents and young children confirms that, on 10 August 2021, it posted its Annual Report and Accounts for the year ended 27 March 2021 together with its Notice of Annual General Meeting (“AGM”). The AGM will be held at 11.00am on 9 September 2021 at the offices of DLA Piper UK LLP, 160 Aldersgate Street, London, EC1A 4HT.  Due to the continuing pandemic, shareholders are encouraged to vote ahead of the meeting by appointing the Chairman of the AGM as proxy. Questions relating to the business of the meeting can be sent by email to: investorrelations@mothercare.com to be received by 11.00 am on 7 September 2021.  Copies of both the Annual Report and Accounts and the AGM Notice...

Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business and pipeline updates, as well as second quarter 2021 financial results. “We have made meaningful progress in advancing our base editing programs in the first half of the year, and importantly, remain on track to submit our first investigational new drug (IND) for BEAM-101 in the second half of this year,” said John Evans, chief executive officer of Beam. “With the initiation of IND-enabling studies for BEAM-201, we are now bringing the versatility...

SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threatening inflammatory conditions, today released the following note authored by its Chairman and CEO, Jim Joyce. Sigyn Therapeutics was founded on the belief that a properly designed medical device could address sepsis and other life-threatening inflammatory conditions that remain beyond the reach of drug therapies. This belief is reflected through our development of Sigyn Therapy. Since December 2020, we reported results from a series of studies that have demonstrated first-in-industry capabilities of Sigyn Therapy to address pathogen sources of inflammation, deadly toxins and relevant inflammatory mediators. Among the therapeutic targets...

OTTAWA, Aug. 10, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that management will participate in Canaccord Genuity 41st Annual Growth Conference. Sebastien St-Louis, Chief Executive Officer, and Trent MacDonald, Chief Financial Officer, will participate in a presentation today, August 10, 2021 at 1:00 p.m. ET. Participants may access a live webcast of the presentation by going to the “Events” page on hexocorp.com or by going directly to the Cannacord Webcast. For more information, please contact your Canaccord Genuity representative. About HEXO Corp (TSX: HEXO; NYSE: HEXO) HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, UP Cannabis, Original...

Follow-up Cullinan Pearl data from Phase 1 portion of ongoing trial showed increased disease control rate (DCR) of 92% in the 100mg dose cohort IND clearance of two immuno-oncology pipeline programs, Cullinan MICA and Cullinan Florentine, with clinical trial starts for each program expected in 2H 2021 Strong balance sheet with cash and investments of $456.3 million as of June 30, 2021 CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced its financial results for the second quarter ended June 30, 2021 and reported on recent business highlights. “Solid execution led to the advancement of our clinical pipeline this quarter,” stated Owen Hughes, Chief Executive Officer of Cullinan Oncology. “We...